Datopotamab deruxtecan (Dato-DXd), another ADC targeting TROP2 with a TOPO-I inhibitor payload, was evaluated in the phase I TROPION-PanTumor01 investigation for HR+/HER2– BC and TNBC, demonstrating ORRs of 26.8% and 31.8%, mPFS of 8.3 and 4.4 mo, and an mDOR of 16.8 mo for TNBC. This evidence concerns the gene ERBB2 and breast cancer.